| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | BIR1; GIRK2; KATP2; KCNJ7; GIRK-2; KATP-2; KIR3.2; hiGIRK2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human KCNJ6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于KCNJ6抗体的代表性文献示例(注：文献为模拟示例，实际引用请核实)：
1. **"KCNJ6 Antibody Localization in Human Brain Regions"**
- 作者：Smith A, et al.
- 摘要：研究使用KCNJ6特异性抗体定位Kir3.2通道蛋白在人脑中的分布，发现其在基底神经节和海马中高表达，提示其与运动控制和记忆功能相关。
2. **"Autoantibodies to KCNJ6 in Cardiac Arrhythmia"**
- 作者：Chen L, et al.
- 摘要：报道在部分特发性心律失常患者血清中检测到KCNJ6抗体，可能通过干扰心脏钾通道电流导致电生理异常。
3. **"KCNJ6 Antibody Validation for Immunohistochemistry"**
- 作者：Wang Y, et al.
- 摘要：系统验证了多种商业KCNJ6抗体的特异性，发现部分抗体存在交叉反应，强调抗体选择对神经科学研究的重要性。
4. **"KCNJ6 Genetic Variants and Antibody Detection in Autism Spectrum Disorders"**
- 作者：Kimura H, et al.
- 摘要：探讨KCNJ6基因突变与自闭症谱系障碍的关联，并发现部分患者存在针对Kir3.2的自身抗体，可能参与神经发育异常机制。
(注：以上为模拟文献，如需真实文献建议通过PubMed或Google Scholar以关键词"KCNJ6 antibody"+"Kir3.2"+"GIRK2"检索近年研究。)
The KCNJ6 antibody is a crucial tool in studying the KCNJ6 gene, which encodes the G protein-activated inward rectifier potassium channel 2 (GIRK2 or Kir3.2). This protein is part of the inwardly rectifying potassium channel family (Kir3), known for regulating cellular excitability by mediating potassium efflux in response to G protein-coupled receptor (GPCR) activation. KCNJ6 is widely expressed in the brain, heart, and other tissues, playing roles in neuronal signaling, cardiac rhythm modulation, and neurotransmitter release.
Antibodies targeting KCNJ6 are used to detect its expression, localization, and function in research settings. They are critical in elucidating KCNJ6's involvement in neurological disorders (e.g., epilepsy, Down syndrome, and addiction mechanisms) and cardiac pathologies. Commercially available KCNJ6 antibodies are typically validated for applications like Western blotting, immunohistochemistry, and immunofluorescence.
Dysregulation of KCNJ6 has been linked to diseases such as Keppen-Lubinsky syndrome, a rare condition characterized by developmental delays and metabolic abnormalities. Research using KCNJ6 antibodies also explores its interaction with signaling molecules (e.g., βγ subunits of G proteins) and its role in synaptic plasticity. As Kir channels are potential therapeutic targets, these antibodies aid in drug discovery and mechanistic studies. Quality validation, including specificity checks via knockout controls, is essential to ensure reliable experimental outcomes.
×
